Compare Stocks: RZLT, RXRX, NTLA, and DMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$28.24 +0.2%	$29.30	$2.45 ▼ $38.33	$1.74B	1.47	378,938 shs	75,287 shs
NTLA Intellia Therapeutics	$12.73	$13.19	$7.95 ▼ $28.25	$1.78B	1.81	5.20 million shs	1.11 million shs
RXRX Recursion Pharmaceuticals	$3.35 -1.6%	$3.32	$2.77 ▼ $7.18	$1.79B	1.03	18.04 million shs	5.00 million shs
RZLT Rezolute	$4.49 -4.4%	$4.85	$1.07 ▼ $11.46	$431.86M	0.58	2.30 million shs	441,247 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	-2.83%	-7.03%	-2.79%	+22.79%	+787.28%
NTLA Intellia Therapeutics	-1.09%	+1.35%	+19.19%	-3.05%	+12.16%
RXRX Recursion Pharmaceuticals	+1.80%	+4.62%	+13.33%	-5.82%	-27.66%
RZLT Rezolute	+1.52%	-6.39%	-0.64%	+17.25%	-34.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$28.24 +0.2%	$29.30	$2.45 ▼ $38.33	$1.74B	1.47	378,938 shs	75,287 shs
NTLA Intellia Therapeutics	$12.73	$13.19	$7.95 ▼ $28.25	$1.78B	1.81	5.20 million shs	1.11 million shs
RXRX Recursion Pharmaceuticals	$3.35 -1.6%	$3.32	$2.77 ▼ $7.18	$1.79B	1.03	18.04 million shs	5.00 million shs
RZLT Rezolute	$4.49 -4.4%	$4.85	$1.07 ▼ $11.46	$431.86M	0.58	2.30 million shs	441,247 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	-2.83%	-7.03%	-2.79%	+22.79%	+787.28%
NTLA Intellia Therapeutics	-1.09%	+1.35%	+19.19%	-3.05%	+12.16%
RXRX Recursion Pharmaceuticals	+1.80%	+4.62%	+13.33%	-5.82%	-27.66%
RZLT Rezolute	+1.52%	-6.39%	-0.64%	+17.25%	-34.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$44.00	55.81% Upside
NTLA Intellia Therapeutics	2.35	Hold	$21.15	66.16% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	140.96% Upside
RZLT Rezolute	2.58	Moderate Buy	$9.38	109.03% Upside

Current Analyst Ratings Breakdown

Latest RZLT, RXRX, NTLA, and DMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00
8/24/2026	DMRA Damora Therapeutics, Inc. Common Stock	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/14/2026	RZLT Rezolute	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	NTLA Intellia Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform	$24.00
7/30/2026	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/30/2026	DMRA Damora Therapeutics, Inc. Common Stock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $40.00
7/27/2026	DMRA Damora Therapeutics, Inc. Common Stock	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
7/21/2026	DMRA Damora Therapeutics, Inc. Common Stock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00
7/17/2026	NTLA Intellia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
NTLA Intellia Therapeutics	$67.67M	26.36	N/A	N/A	$5.80 per share	2.19
RXRX Recursion Pharmaceuticals	$74.68M	23.98	N/A	N/A	$2.14 per share	1.56
RZLT Rezolute	N/A	N/A	N/A	N/A	$1.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
RZLT Rezolute	-$74.41M	-$0.82	N/A	N/A	N/A	N/A	-58.82%	-54.48%	9/16/2026 (Estimated)

Latest RZLT, RXRX, NTLA, and DMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/16/2026	Q4 2026	RZLT Rezolute	-$0.13	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
NTLA Intellia Therapeutics	N/A	6.65	6.65
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
RZLT Rezolute	N/A	15.84	15.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
NTLA Intellia Therapeutics	88.77%
RXRX Recursion Pharmaceuticals	89.06%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
NTLA Intellia Therapeutics	3.50%
RXRX Recursion Pharmaceuticals	6.65%
RZLT Rezolute	14.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
NTLA Intellia Therapeutics	600	140.13 million	135.22 million	Optionable
RXRX Recursion Pharmaceuticals	400	535.34 million	499.74 million	Optionable
RZLT Rezolute	40	96.29 million	82.06 million	Optionable

RZLT, RXRX, NTLA, and DMRA Headlines

Recent News About These Companies

Rezolute Shares to Show Strength Towards Upcoming Ersodetug Catalysts, Wedbush Says

August 25, 2026 | finance.yahoo.com

Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DE

August 25, 2026 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by Brokerages

August 19, 2026 | marketbeat.com

Bank of New York Mellon Corp Sells 481,913 Shares of Rezolute, Inc. $RZLT

August 17, 2026 | marketbeat.com

Rezolute, Inc. $RZLT Shares Acquired by Dimensional Fund Advisors LP

August 14, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)

July 30, 2026 | theglobeandmail.com

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

July 21, 2026 | globenewswire.com

Rezolute Inc.

June 29, 2026 | marketwatch.com

FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

June 25, 2026 | stockhouse.com

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

June 17, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)

June 12, 2026 | theglobeandmail.com

Positive Signs As Multiple Insiders Buy Rezolute Stock

June 10, 2026 | finance.yahoo.com

RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?

June 4, 2026 | zacks.com

Rezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital Hyperinsulinism

June 4, 2026 | quiverquant.comQ

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

June 4, 2026 | globenewswire.com

Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)

June 3, 2026 | theglobeandmail.com

Rezolute upgraded at Citizens after late-stage trial data for lead asset

June 3, 2026 | seekingalpha.com

Rezolute rises after late-stage trial update

June 3, 2026 | msn.com

Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

June 2, 2026 | benzinga.com

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

June 2, 2026 | globenewswire.com

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT, RXRX, NTLA, and DMRA Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$28.24 +0.06 (+0.21%)

As of 12:47 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Intellia Therapeutics NASDAQ:NTLA

$12.72 -0.01 (-0.07%)

As of 01:12 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.34 -0.06 (-1.62%)

As of 01:13 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Rezolute NASDAQ:RZLT

$4.50 -0.20 (-4.16%)

As of 01:12 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RZLT, RXRX, NTLA, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RZLT, RXRX, NTLA, and DMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RZLT, RXRX, NTLA, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT, RXRX, NTLA, and DMRA Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Intellia Therapeutics NASDAQ:NTLA

Recursion Pharmaceuticals NASDAQ:RXRX

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RZLT, RXRX, NTLA, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RZLT, RXRX, NTLA, and DMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RZLT, RXRX, NTLA, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT, RXRX, NTLA, and DMRA Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Intellia Therapeutics NASDAQ:NTLA

Recursion Pharmaceuticals NASDAQ:RXRX

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools